medigraphic.com

2006, Number 3

<< Back Next >>

Med Sur 2006; 13 (3)

Thrombolysis at 97, yes or no? Case-report and review of the medical literature

Herrera-García JC, Nader-Kawachi J, Zavala-García C, Motola-Kuba D, Hernández-Estrada S, Flores-García L, Ferrusquía-Acosta JA

Language: Spanish
References: 12
Page: 136-138
PDF size: 225.82 Kb.


ABSTRACT

The risk for presenting cerebral vascular disease (CVD) according to age increases exponentially. In 1995, the FDA approved the thrombolytic therapy with Recombinant Tissue Plasminogen Activator (rt-PA) for patients with acute thrombotic CVD. Several studies have shown the benefits in patients receiving this treatment within the first six hours of the event. There is concerning due to the adverse effects related to this treatment in elderly persons, although cases receiving thrombolysis have been reported in patients up to 102 years old. In this report we present a case of a 97 year old patient who presented at our Institution with a CVD, which was treated with rt-PA, resulting in an excellent outcome. We also present a concise review of the literature.


REFERENCES

  1. Ocava LC. Clin Geriatr Med 2006; 22: 135–154.

  2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.

  3. Kwiatkowski TG, Libman RB, Frankel M. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340: 1781-7.

  4. Kaste M. Thrombolysis: What more does it take. Stroke 2005; 36: 200-202.

  5. Del Zoppo GJ et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32(1): 78-86.

  6. Hacke W. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999; 53(7 Suppl 4): S3-S4.

  7. Adams HP. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association. Stroke 2003; 34: 1056–83.

  8. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.

  9. Tanne D, Gorman MJ, Bates VE. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000; 31: 370-5.

  10. Simon JE, Sandler DL, Pexman JH, Hill MD, Buchan AM. Calgary Stroke Programme. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischemic stroke? The Calgary experience. Age and Ageing 2004; 33: 143–149.

  11. Beletsky V, Hachinsky V. Stroke thrombolysis in the elderly: Risk or benefit? Neurology 2006 (67): 183-184.

  12. INCMNSZ. Manual de Terapéutica Médica: Neurología. Mc-Graw-Hill Interamericana 2006: 438-445.




2020     |     www.medigraphic.com